<DOC>
	<DOCNO>NCT01773408</DOCNO>
	<brief_summary>This Phase 1/1b , open-label study evaluate safety pharmacokinetics escalate dos RO5503781 single agent combination cytarabine participant acute myelogenous leukemia . In Part 1 , RO5503781 administer escalate dos single agent , Part 2 , RO5503781 administer combination cytarabine . An optional Part 3 RO5503781 administer cytarabine anthracycline may consider . In Part 4 , safety pharmacokinetic profile optimize formulation RO5503781 combination cytarabine assess .</brief_summary>
	<brief_title>A Study RO5503781 Single Agent Combination With Cytarabine Participants With Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Documented/confirmed acute myelogenous leukemia ( AML ) , except acute promyelocytic leukemia Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Part 1 Part 2 , participant enrol extension/tail portion , Part 3 Part 4 must ECOG performance status 0 1 All nonhematological adverse event prior chemotherapy , surgery radiotherapy must resolve National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) Grade le equal ( &lt; /= ) 2 prior start therapy Adequate hepatic renal function Willing submit blood sample bone marrow sampling require protocol Additional inclusion criterion Parts 14 may apply . Participants receive investigational commercial agent therapy administer intention treat malignancy within 14 day first receipt study drug , exception hydroxyurea define protocol History allergic toxic reaction attribute cytarabine ( Part 2 ) history allergic reaction component formulate product Current evidence central nervous system ( CNS ) leukemia Participants severe and/or uncontrolled medical condition condition could affect participation study Participants evidence electrolyte imbalance great equal ( &gt; /= ) Grade 2 correct prior study initiation Pregnant breastfeed woman Human immunodeficiency virus ( HIV ) positive participant receive antiretroviral therapy Participants refuse potentially receive blood product and/or hypersensitivity blood product Additional exclusion criterion Parts 14 may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>